Sarepta Therapeutics, Inc. to Post FY2024 Earnings of $6.66 Per Share, William Blair Forecasts (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Stock analysts at William Blair reduced their FY2024 earnings estimates for Sarepta Therapeutics in a research note issued on Wednesday, April 17th. William Blair analyst T. Lugo now expects that the biotechnology company will post earnings per share of $6.66 for the year, down from their previous estimate of $6.74. The consensus estimate for Sarepta Therapeutics' current full-year earnings is $2.14 per share. William Blair also issued estimates for Sarepta Therapeutics' FY2025 earnings at $14.91 EPS.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The firm had revenue of $396.80 million for the quarter, compared to analysts' expectations of $387.18 million. During the same quarter last year, the business earned ($1.24) earnings per share. The business's revenue was up 53.6% on a year-over-year basis.

SRPT has been the topic of several other research reports. TheStreet upgraded shares of Sarepta Therapeutics from a "d" rating to a "c-" rating in a report on Monday, March 4th. Mizuho raised their price target on Sarepta Therapeutics from $130.00 to $145.00 and gave the stock a "buy" rating in a research note on Wednesday, February 14th. Citigroup raised their price target on Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a "buy" rating in a research note on Thursday, February 29th. Barclays raised their price target on Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an "overweight" rating in a research note on Thursday, February 29th. Finally, BMO Capital Markets began coverage on Sarepta Therapeutics in a research note on Wednesday, January 31st. They issued an "outperform" rating and a $170.00 price target for the company. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $158.38.

Sarepta Therapeutics Trading Down 0.8 %

Shares of Sarepta Therapeutics stock traded down $0.93 on Friday, hitting $115.62. The stock had a trading volume of 641,078 shares, compared to its average volume of 985,430. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32. Sarepta Therapeutics has a one year low of $55.25 and a one year high of $159.89. The stock has a market cap of $10.86 billion, a price-to-earnings ratio of -18.89 and a beta of 0.94. The stock's 50-day simple moving average is $126.52 and its two-hundred day simple moving average is $110.41.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 1,200 shares of the firm's stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.30, for a total transaction of $153,960.00. Following the completion of the transaction, the chief financial officer now owns 39,114 shares of the company's stock, valued at $5,018,326.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Kathryn Jean Boor sold 761 shares of Sarepta Therapeutics stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the transaction, the director now owns 7,516 shares of the company's stock, valued at approximately $923,941.88. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Ian Michael Estepan sold 1,200 shares of Sarepta Therapeutics stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.30, for a total value of $153,960.00. Following the completion of the transaction, the chief financial officer now directly owns 39,114 shares of the company's stock, valued at approximately $5,018,326.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 22,096 shares of company stock valued at $2,739,419. 7.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Large investors have recently modified their holdings of the stock. Mather Group LLC. purchased a new position in shares of Sarepta Therapeutics in the 1st quarter worth about $28,000. Montag A & Associates Inc. bought a new stake in Sarepta Therapeutics in the 3rd quarter worth about $30,000. Cary Street Partners Investment Advisory LLC increased its holdings in Sarepta Therapeutics by 154.0% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company's stock worth $31,000 after buying an additional 154 shares in the last quarter. KB Financial Partners LLC bought a new stake in Sarepta Therapeutics in the 1st quarter worth about $36,000. Finally, Qube Research & Technologies Ltd bought a new stake in Sarepta Therapeutics in the 3rd quarter worth about $33,000. Hedge funds and other institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.